Solid Bioscience Stock Price, News & Analysis

Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of inducement awards to new employees. The company issued 105,330 restricted stock units (RSUs) to seven newly hired employees.

The RSUs will vest over a four-year period, with equal installments vesting annually on the grant date anniversary. The awards were granted under the Company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment acceptance.

Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on precision genetic medicines for neuromuscular and cardiac diseases, has granted 34,550 restricted stock units (RSUs) to two new employees. The RSUs will vest over four years, with 25% vesting annually on each grant date anniversary. The grants were issued under the Company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment. Vesting is contingent upon continued employment with Solid Biosciences through each vesting date.

Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, announced its participation in the upcoming Jefferies Global Healthcare Conference. President and CEO Bo Cumbo and Chief Medical Officer Gabriel Brooks will engage in a fireside chat on June 4, 2025, at 2:00 pm ET. The presentation will be accessible via live webcast on the company's website's Investor Events page, with a replay available for 30 days afterward. Institutional investors can arrange meetings with management through their Jefferies representatives.

Solid Biosciences (NASDAQ: SLDB) reported Q1 2025 financial results and provided updates on its gene therapy pipeline. The company's cash position strengthened to $306.9 million, extending runway into H1 2027. Net loss widened to $39.3 million from $24.3 million year-over-year.

Key pipeline updates include: 1) Ongoing participant dosing in the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, with positive initial data showing robust microdystrophin expression and improved biomarkers; 2) FDA-cleared IND for SGT-212 for Friedreich's Ataxia, with first participant dosing expected in H2 2025; 3) Planned IND submission for SGT-501 for CPVT in H1 2025.

The company's proprietary capsid AAV-SLB101 has secured 19 partnership agreements, with more expected. R&D expenses increased to $30.9 million, primarily due to increased costs for SGT-003 development.

Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of 81,000 restricted stock units (RSUs) to seven newly hired employees. The RSUs will vest over a four-year period, with 25% vesting annually on each grant date anniversary. The equity awards were granted under the Company's 2024 Inducement Stock Incentive Plan and are contingent upon continued employment through each vesting date. These grants were made as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its upcoming participation in The Citizens Life Sciences Conference.

The company's President and CEO, Bo Cumbo, will engage in a fireside chat scheduled for Wednesday, May 7, at 12:30 pm ET. Interested parties can access the presentation through a live webcast available on the Events page of the company's Investors section website.

Key Details:

• Event: The Citizens Life Sciences Conference
• Format: Fireside Chat
• Date & Time: May 7, 12:30 pm ET
• Replay Availability: 30-day archive access

Institutional investors seeking management meetings during the conference are advised to contact their Citizens representative.

Solid Biosciences will present data from their INSPIRE DUCHENNE Phase 1/2 trial for SGT-003, a next-generation gene therapy for Duchenne muscular dystrophy, at the upcoming ASGCT Annual Meeting in New Orleans.

The company will deliver three oral presentations and four poster presentations, highlighting:

• Initial safety and biomarker data from the INSPIRE DUCHENNE study
• Insights into AAV-SLB101, a novel muscle-tropic capsid
• Gene transfer potential in natural seropositivity cases
• Advanced quantification and characterization methods

CEO Bo Cumbo emphasized the company's progress in next-generation capsid design and their commitment to developing precision genetic medicines for rare neuromuscular and cardiac diseases. The presentations will take place between May 13-17, 2025, featuring research from leading scientists and medical professionals.

Solid Biosciences (SLDB), focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in two upcoming investor conferences.

The company will present at the 24th Annual Needham Virtual Healthcare Conference on April 10, 2025, at 2:15 pm ET, featuring President and CEO Bo Cumbo and Chief Medical Officer Gabriel Brooks. A live webcast will be available on the company's website with a 90-day replay period.

Additionally, management will conduct one-on-one meetings at the Piper Sandler Spring Biopharma Symposium in Boston, MA on April 17, 2025. Institutional investors can arrange meetings through their Needham or Piper Sandler representatives.

Solid Biosciences (NASDAQ: SLDB) has announced the granting of 43,374 restricted stock units (RSUs) to three newly hired employees. The RSUs are structured with a four-year vesting schedule, with 25% vesting annually on each grant date anniversary. The equity awards, issued under the Company's 2024 Inducement Stock Incentive Plan, are contingent upon continued employment through each vesting date. This compensation package was designed as an inducement for employment and complies with Nasdaq Listing Rule 5635(c)(4).